微創機器人-B(02252.HK):R-ONE®血管介入手術機器人完成註冊臨牀試驗入組
格隆匯5月26日丨微創機器人-B(02252.HK)公告,公司董事會欣然宣佈由公司和法國RobocathS.A.S聯合在華成立的合資公司知脈(上海)機器人有限公司引進的R-ONE®血管介入手術機器人已完成註冊臨牀試驗入組,成爲國內首款完成多中心註冊臨牀試驗入組的心血管介入機器人系統。本次註冊臨牀試驗由301醫院牽頭,山西省心血管病醫院、梅州市人民醫院及新疆維吾爾自治區人民醫院共同參與。於臨牀試驗期間,R-ONE®完成了雙支病變、同軸性差的大角度扭曲血管病變、瀰漫長病變、鈣化性病變、開口異位以及次全閉塞等多種疑難複雜病例,並多次完成三連臺手術,充分驗證了R-ONE®的穩定性和可靠性。
R-ONE®是基於主從控制技術的血管介入導航控制系統,通過多項核心專利,輔助醫生更加精準、高效、可靠的完成PCI手術,且學習曲線短,同時可減少手術併發症。此外,使用R-ONE®時,術者可坐在防輻射控制檯後,通過遠端操控,在完成精確手術操作的同時有效減少了在射線下的暴露時間。
R-ONE®完成註冊臨牀試驗入組是本公司在泛血管介入領域的另一重大突破,標誌着中國的機器人輔助血管介入手術邁上新臺階,爲挑戰更精準、更智能、更微創傷的血管介入手術奠定了重要的基礎。
未來,公司將繼續加強與臨牀專家的緊密合作,利用集團化運營優勢,聯合全國更多學術專家,將優質醫療資源下沉,爲更多患者提供精準、智能、普惠的機器人手術解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.